Title of article :
Up-Regulation of miR-21, miR-25, miR-93, and miR-106b in Gastric Cancer
Author/Authors :
Larki, Pegah Department of Medical Genetics - School of Medicine - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Ahadi, Alireza Department of Medical Genetics - School of Medicine - Shahid Beheshti University of Medical Sciences, Tehran, Iran , zare, Ali Department of Medical Genetics - School of Medicine - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Tarighi, Shahriar Department of Medical Laboratory Sciences - School of Allied Medical Sciences - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Zaheri, Mahrokh Gastroenterology and Liver Diseases Research Center - Research Institute for Gastroenterology and Liver Diseases - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Souri, Mojgan Gastroenterology and Liver Diseases Research Center - Research Institute for Gastroenterology and Liver Diseases - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Zali, Mohammad Reza Gastroenterology and Liver Diseases Research Center - Research Institute for Gastroenterology and Liver Diseases - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Ghaedi, Hamid Department of Medical Genetics - School of Medicine - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Omrani, Mir Davood Department of Medical Genetics - School of Medicine - Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract :
Background: Differential expression profile of microRNAs (miRNAs) could be a diagnosis signature for
monitoring gastric cancer (GC) progression. In this study, we focus on the comparison of expression levels of
miR-21, miR-25, miR-93, miR-106b, and miR-375 during the sequential pattern of GC development, including
normal gastric, gastric dysplasia, and GC sample. Methods: We used SYBR Green-based quantitative-PCR to
quantify miRNAs expression. Results: Our analysis revealed the increased expression levels of miR-21 (p = 0.034),
miR-25 (p = 0.0003), miR-93 (p = 0.0406), and miR-106b (p = 0.023) in GC samples. In addition, GC patients with
positive lymph node metastasis showed the up-regulation of miR-25, miR-93, and miR-106b (p < 0.05).
Conclusion: Our findings suggested that the expression of miR-21, miR-25, miR-93, and miR-106b altered in GC,
and some of them may be further investigated as biomarkers for GC early detection and prognosis prediction.
